Compare Nutanix Inc (NTNX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Twist Bioscience Corp — how do they compare? Nutanix Inc trades at $67 (market cap $18.10B), while Twist Bioscience Corp trades at $125.52 (market cap $8.26B). The key difference: Nutanix Inc is far larger — about 2.2× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| NTNX | TWST | |
|---|---|---|
Market Cap | $18.10B | $8.26B |
Sector | Technology | Health |
52-Week High | $81.12 | $153.10 |
52-Week Low | $34.41 | $24.16 |
Enterprise Value | $17.25B | $8.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $67.49, down 0.84% on the day, with strong technical indicators showing a bullish trend. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49. Recent recognition in Gartner's Magic Quadrant for container management and strong conference presentations highlight ongoing business momentum. Valuation metrics show a P/E of 12.95 and P/S of 6.85, with exceptional profitability margins including 86.8% gross margin and 52.81% net income margin.
The outlook remains positive with analyst consensus price target of $77.20 representing 14% upside potential. Key opportunities include continued hybrid cloud adoption and AI infrastructure demand, while risks involve competitive pressures and execution challenges in maintaining growth momentum. Cash flow trends show improvement with 2026 operating cash flow projected at $917 million, supporting the company's strategic investments.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
